Neurobehavioral Mechanisms of Social Isolation and Loneliness in Serious Mental Illness
Part of paid clinical trials in Charlestown, Massachusetts.
- Sponsor
- Massachusetts General Hospital
- Study ID
- NCT04940663
- Status
- Recruiting
Conditions
- Psychosis
- Schizophrenia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- EMA — BEHAVIORALParticipants will complete surveys about their feelings and social habits through a smartphone app (EMA)
Study Details
The proposed research will test the hypothesis that objective social isolation and loneliness are linked to neurobehavioral mechanisms involved in social perception and motivation in individuals with and without serious mental illness. Moreover, it will investigate the specific dynamic interactions among these experiences in daily life and how they, and their neurobehavioral predictors, are linked to day-to-day functioning. The findings of this project could provide novel targets for therapeutics aimed at improving functioning and overall quality of life in individuals with serious mental illnesses, as well as quantitative phenotypes for use in early detection efforts.
Key Dates
- Start date
- Jul 13, 2022
- Status verified
- May 2026
- Primary completion
- Jun 30, 2026
- Completion
- Jun 30, 2026
Study Design
- Enrollment
- 120 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- BASIC_SCIENCE
Arms
- Other: Ecological Momentary AssessmentEMA collected daily (4x/day) for two weeks
Primary Outcome Measure
Trait level social isolation and loneliness [ Time Frame: 6 months ]
Central Contacts
- Daphne J Holt, MD, PhD617-726-7618
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Massachusetts General Hospital | Charlestown | Massachusetts | 02129 |
Find similar trials in Charlestown, MA
Related Studies
- Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric PopulationsRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- CLOZAPINE Response in Biotype-1PHASE4 · Recruiting · University of Texas Southwestern Medical Center · Hartford, Connecticut
- Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaPHASE3 · Recruiting · Reviva Pharmaceuticals · Phoenix, Arizona
- Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory HallucinationsRecruiting · Boston VA Research Institute, Inc. · Brockton, Massachusetts